Law Office of Brodsky & Smith, LLC announces an investigation of XBiotech Inc. (“XBiotech” or the “Company”) (Nasdaq: XBIT) for potential violations of federal securities laws and breaches of the XBiotech Board’s fiduciary duties.
Click here to learn more about the investigation http://brodsky-smith.com/1024-xbit-xbiotech-inc.html, or call: 877-534-2590. There is no cost or obligation to you.
The investigation concerns a securities class action lawsuit commenced in the United States District Court for the Western District of Texas. The complaint alleges that the Defendants made false and misleading statements including (1) failing to disclose that a fewer number of per protocol patients were available for primary endpoint evaluation in the Phase III Study; (2) the data from 72 patients of the Phase III Study was compromised; (3) XBiotech did not adequately sample patients to accommodate data loss; and (4) as a result of not properly sampling patients, the Phase III Study would have reduced statistical power to demonstrate the proposed outcome.
If you purchased shares of XBiotech common stock between April 15, 2015 and November 23, 2015, and wish to discuss the investigation, or if you have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC before February 1 , 2016, who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004, by e-mail at [email protected], by visiting http://brodsky-smith.com/1024-xbit-xbiotech-inc.html, or calling toll free 877-LEGAL-90.
Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and successfully recovered millions of dollars for our clients and shareholders.
Attorney advertising. Prior results do not guarantee a similar outcome.